Combined capital will support the ongoing Phase 2a clinical trial of procizumab in cardiogenic shock Hennigsdorf/Berlin, November 13, 2025 – 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) today announced the ...
Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli ™ , the First FDA-Approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback